The potential dangers of treating head injury patients with corticosteroids

Bibliography

• ACS COMMITTEE ON TRAUMA: ATLS Instructor Course Manual. American College of Surgeon, Chicago, USA (1997).
   Google Scholar
• RHODES JKJ: Actions of glucocorticoids and related molecules after traumatic brain injury. Curr. Opin. Crit. Care Med. (2003) 9:86–91.
   PubMedGoogle Scholar
• ••An interesting review on possiblemechanisms of action of corticosteroids In traumatic brain injury.
   Google Scholar
• MCINTOSH TK, SMITH DH, MEANEY DF, KOTAPKA MJ, GENNARELLI TA, GRAHAM DI: Neuropathological sequelae of traumatic brain injury: relationship to neurochemical and biomechanical mechanisms. Lab. Invest. (1996) 74:315–342.
   PubMed Web of Science ®Google Scholar
• RAMILO O, SAEZ-LLORENS X, MERTSOLA J et al: Tumor necrosis factor alphaicachectin and interleukin 1 beta initiate meningeal inflammation. J. Exp. Med. (1990) 172:497–507.
   PubMed Web of Science ®Google Scholar
• QUAGLIARELLO VJ, WISPELWEY B, LONG WJ JR, SCHELD WM: Recombinant human interleukin-1 induces meningitis and blood-brain barrier injury in the rat. Characterization and comparison with tumor necrosis factor. J. Glib. Invest. (1991) 87:1360–1366.
   Google Scholar
• KIM KS, WASS CA, CROSS AS, OPAL SM: Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. Lymphokine Cytokine Res. (1992) 11:293–298.
   PubMedGoogle Scholar
• MARUO N, MORITA I, SHIRAO M, MURATA S: IL-6 increases endothelial permeability in vitro. Endocrinology (1992) 131:710–714.
   PubMed Web of Science ®Google Scholar
• MEGYERI P, ABRAHAM CS, TEMESVARI P, KOVACS J, VAS T, SPEER CP: Recombinant human tumor necrosis factor alpha constricts pial arterioles and increases blood-brain barrier permeability in newborn piglets. Neurosci. Lett. (1992) 148:137–140.
   PubMed Web of Science ®Google Scholar
• DE VRIES HE, B LOM-ROOSEMALEN MC, VAN OOSTEN M et al: The influence of cytokines on the integrity of the blood-brain barrier in vitro. Neuroimmunol (1996) 64:37–43.
   PubMed Web of Science ®Google Scholar
• FEUERSTEIN G, WANG X, BARONE FC: Cytokines in brain ischemia - the role of TNF alpha. Cell. Mol Neurobiol (1998) 18:695–701.
   PubMed Web of Science ®Google Scholar
• HOLMIN S, MATHIESEN T: Intracerebral administration of interleukin- lbeta and induction of inflammation, apoptosis, and vasogenic edema. Neuracurg. (2000) 92:108–120.
   PubMed Web of Science ®Google Scholar
• TOULMOND S, ROTHWELL NJ: Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat. Brain Res. (1995) 671:261–266.
   PubMed Web of Science ®Google Scholar
• SHOHAMI E, BASS R, WALLACH D, YAMIN A, GALLILY R. Inhibition of tumor necrosis factor alpha (TNFalpha) activity in rat brain is associated with cerebroprotection after closed head injury. Cereb. Blood Flow Metab. (1996) 16:378–384.
   Google Scholar
• KONTOS HA, POVLISHOCK JT: Oxygen radicals in brain injury. Cent. Nerv. Syst. Trauma (1986) 3:257–263.
   PubMedGoogle Scholar
• BRAUGHLER JM, HALL ED: Central nervous system trauma and stroke. I. Biochemical considerations for oxygen radical formation and lipid peroxidation. Free Radic. Biol. Med. (1989) 6:289–301.
   PubMed Web of Science ®Google Scholar
• HALL ED, BRAUGHLER JM: Central nervous system trauma and stroke. II. Physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. Free Radic. Biol. Med. (1989) 6:303–313.
   PubMed Web of Science ®Google Scholar
• HALL ED, BRAUGHLER JM: Free radicals in CNS injury. Res. Publ. Assoc. Res. Nerv. Ment. Dis. (1993) 71:81–105.
   PubMedGoogle Scholar
• ILDAN F, POLAT S, ONER A, ISBIR T, CETINALP E, KAYA M et al.: The effect of the treatment of high-dose methylprednisolone on Na(÷)-K(÷)/Mg(+2)ATPase activity and lipid peroxidation and ultrastructural findings following cerebral contusion in rat. Surg. Neurol (1995) 44:573–580.
   PubMed Web of Science ®Google Scholar
• ALMAWI WY, BEYHUM HN, RAHME AA, RIEDER MJ: Regulation of cytokine and cytokine receptor expression by glucocorticoids. Leukoc. Biol. (1996) 60:563–572.
   PubMed Web of Science ®Google Scholar
• BRAUGHLER JM: Lipid peroxidation- induced inhibition of gamma-aminobutyric acid uptake in rat brain synaptosomes: protection by glucocorticoids. Neurochem. (1985) 44:1282–1288.
   PubMed Web of Science ®Google Scholar
• ANDERSON DK, MEANS ED: Iron-induced lipid peroxidation in spinal cord: protection with mannitol and methylprednisolone. I Free Radic. Biol. Med. (1985) 1:59–64.
   PubMedGoogle Scholar
• HALL ED: High-dose glucocorticoid treatment improves neurological recovery in head-injured mice. J. Neurosurg. (1985) 62:882–887.
   PubMed Web of Science ®Google Scholar
• JEEVARATNUM DR, MENON DK: Survey of intensive care of severely head injured patients in the United Kingdom. BMJ(1996) 312:944–947.
   PubMed Web of Science ®Google Scholar
• GHAJAR J, HARIRI R, NARAYAN R, LACONO L, FIRLIK K, PATTERSON R: Survey of critical care management of comatose head injured patients in the United States. Grit. Care Med. (1995) 23:560–567.
   PubMed Web of Science ®Google Scholar
• CRASH TRIAL COLLABORATORS: Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (1VIRC CRASH trial): randomised placebo-controlled trial. Lancet (2004) 364:1321–1328.
   PubMed Web of Science ®Google Scholar
• ••The largest trial on corticosteroidsIn head trauma.
   Google Scholar
• ALDERSON P, ROBERTS I: Corticosteroids in acute traumatic brain injury: systematic review of randomised controlled trials. BMJ(1997) 314:1855–1859.
   PubMed Web of Science ®Google Scholar
• BRACKEN MB, SHEPARD MJ, COLLINS WF et al.: A randomised controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury. N Engl. I Med. (1990) 322:1405–1411.
   PubMed Web of Science ®Google Scholar
• •NASCIS-2 trial on corticosteroid treatment in spinal injured patients.
   Google Scholar
• BRACKEN M, SHEPARD M, HOLFORD T et al: Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury: results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. JAMA (1997) 277: 1597-1604.
   Google Scholar
• •NASCIS-3 trial on corticosteroid treatment in spinal injured patients.
   Google Scholar
• BRACKEN MB, SHEPARD MJ, COLLINS WF, Jr et al: Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the Second National Acute Spinal Cord Injury Study. Neurosurg. (1992) 63:704–713.
   Google Scholar
• BRACKEN MB, SHEPARD MJ, HOLFORD TR et al.: Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. Neurosurg. (1998) 89:699–706.
   Google Scholar
• HURLBERT RJ: Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. I Neurosurg. (2000) 93\(Suppl. 1):1–7.
   Google Scholar
• NESATHURAI S: Steroids and spinal cord injury: revisiting the NASCIS 2 and NASCIS 3 trials. I Trauma (1998) 45:1088–1093.
   PubMed Web of Science ®Google Scholar
• COLEMAN WP, BENZEL D, CAHILL DW et al.: A critical appraisal of the reporting of the National Acute Spinal CordInjury Studies (II and III) of methylprednisolone in acute spinal cord injury. J. Spinal Disord. (2000) 13:185–199.
   PubMedGoogle Scholar
• ••An accurate analysis of the limits ofNASCIS trials.
   Google Scholar
• FEHLINGS MG: Editorial: recommendations regarding the use of methylprednisolone in acute spinal cord injury: making sense out of the controversy. Spine (2001) 26\(Suppl. 24):556–557.
   Google Scholar
• •The editorial suggests a practical approach to the use of methylprednisolone in acute spinal cord injury.
   Google Scholar
• CRASH TRIAL COLLABORATORS: Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet (2005) 365(9475):1957–1959.
   PubMed Web of Science ®Google Scholar
• TEJADA ANTIGAS A, BELLO DRONDA S, CHACON VALLES E et al: Risk factors for nosocomial pneumonia in critically ill trauma patients. Grit. Care. Med. (2001) 29:304–309.
   PubMed Web of Science ®Google Scholar
• DIMOPOULOS G, PIAGNERELLI M, BERRE J, EDDAFALI B, SALMON I, VINCENT JL: Disseminated aspergillosis in intensive care unit patients: an autopsy study' Chemother. (2003) 15:71–75.
   Google Scholar
• KISTEMANN T, HUNEBURG H, EXNER M, VACATA V, ENGELHART S: Role of increased environmental Aspergillosis exposure for patients with chronic obstructive pulmonary disease (COPD) treated with corticosteroids in an intensive care unit. Int. I Hyg. Environ. Health (2002) 204:347–351.
   PubMed Web of Science ®Google Scholar
• BRACKEN MB, SHEPARD MJ, HELLENBRAND KG et al.: Methylprednisolone and neurological function 1 year after spinal cord injury: results of the National Acute Spinal Cord Injury Study." Neurosurg. (1985) 63:704–713.
   Google Scholar
• ALDERSON P, ROBERTS I: Corticosteroids for acute traumatic brain injury. Cochrane Database Syst. Rev (2005) 1:CD000196.
   Google Scholar
• CRONIN L, COOK DJ, CARLET J et al: Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Grit. Care Med. (1995) 23:1430–1439.
   PubMed Web of Science ®Google Scholar
• BONE RC, FISHER CJ JR, CLEMMER TP, SLOTMAN GJ, METZ CA, BALK RA: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl. I Med. (1987) 317:653–638.
   PubMed Web of Science ®Google Scholar
• LUCE JM, MONTGOMERY B, MARKS JD, TURNER J, METZ CG, MURRAY JF: Ineffectiveness of high-dose methylprednisolone in preventing parenchimal lung injury and improving mortality in patients with septic shock. Am. Rev. Respir. Dis. (1988) 138:62–68.
   PubMed Web of Science ®Google Scholar
• BERNARD GR, LUCE JM, SPRUNG CL et al: High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl. I. Med. (1987) 317:565–570.
   PubMed Web of Science ®Google Scholar
• SAUERLAND S, NAGELSCHMIDT M, MALLMANN P, NEUGEBAUER EA: Risks and benefits of preoperative high dose methyprednisolone in surgical patients: a systematic review. Drug Sal: (2000) 23:449–461.
   PubMed Web of Science ®Google Scholar
• •A review of trials in which short-term, high-dose corticosteroid treatment was applied to spine surgery.
   Google Scholar
• DOUGLAS IS: Possible explanations for the results of CRASH. Lancet (2005) 365:212.
   PubMed Web of Science ®Google Scholar
• YOUNG B, OTT L, DEMPSEY R, HAACK D, TIBBS P: Relationship between admission hyperglycaemia and neurologic outcome of severely brain-injured patients. Ann. Surg. (1989) 210:466–472.
   PubMed Web of Science ®Google Scholar
• STAMBROOK M, MOORE AD, KOWALCHUK S, KASSUM DA, PETERS LC, MCCLARTY BM et al: Early metabolic and neurologic predictors of long-term quality of life after closed head injury. Can. J. Surg. (1990) 33:115–118.
   PubMed Web of Science ®Google Scholar
• LAM AM, WIN HR, CULLEN BE SUNDLING N: Hyperglycemia and neurological outcome in patients with head injury. I Neurosurg. (1991) 75:545–551.
   PubMed Web of Science ®Google Scholar
• ROVLIAS A, KOTSOU S: The influence of hyperglycaemia on neurological outcome in patients with severe head injury. Neurosurgery (2000) 46:335–342.
   PubMed Web of Science ®Google Scholar
• WALIA S, SUTCLIFFE AJ: The relationship between blood glucose, mean arterial pressure and outcome after severe head injury: an observational study. Injury (2002) 33:339–344.
   PubMed Web of Science ®Google Scholar
• JEREMITSKY E, OMERT LA, DUNHAM CM, WILBERGER J, RODRIGUEZ A: The impact of hyperglycemia on patients with severe brain injury. 'Trauma (2005) 58:47–50.
   PubMed Web of Science ®Google Scholar
• MARGULIES DR, HIATT JR, VINSON D JR, SHABOT MM: Relationship of hyperglycaemia and severity of illness to neurological outcome in head injury patients. Ann. Surg. (1994) 60:387–390.
   Google Scholar
• VAN DEN BERGHE G, WOUTERS P, WEEKERS F et al.: Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. (2001) 345:1359–1367.
   Google Scholar
• KRINSLEY JS: Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin. Proc. (2004) 79:992–1000.
   PubMed Web of Science ®Google Scholar
• VAN DEN BERGHE G, WOUTERS PJ, BOUILLON R et al.: Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit.Care Med. (2003) 31:359–366.
   Google Scholar
• MALMBERG K, RYDEN L, EFENDIC S et al.: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. CollCardiol (1995) 26:57–65.
   Web of Science ®Google Scholar
• VAN DEN BERGHE G: How does blood glucose control with insulin save lives in intensive care. J. Clin. Invest. (2004) 114:1187–1195.
   PubMed Web of Science ®Google Scholar
• ••A complete update on the effects ofhyperglycaemia and control by insulin.
   Google Scholar
• KASPERLIK-ZALUSKA AA, SLOWINSKA-SZREDNICKA J, BONICKI W, KUNICKI J: Possible explanations for the results of CRASH. Lancet (2005) 365:212–213.
   PubMed Web of Science ®Google Scholar
• HENZEN C, SUTER A, LERCH E, URBINELLI R, SCHOMO XH, BRINER VA: Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet (2000) 355:542–545.
   PubMed Web of Science ®Google Scholar
• CERNAK I, SAVIC VJ, LAZAROV A, JOKSIMOVIC M, MARKOVIC S: Neuroendocrine responses following graded traumatic brain injury in male adults. Brain Inj. (1999) 12:1005–1015.
   Google Scholar
• AGHA A, ROGERS B, SHERLOCK M, O'KELLY P, TORMEY W, PHILLIPS J: Anterior pituitary dysfunction in survivors of traumatic brain injury. J. Clin. Endocrinol Metab. (2004) 89:4929–4936.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN SA, OBEROI AL, GILKISON CR, MASEL BE, URBAN RJ: Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury. I Clin. Endocrinol Metab. (2001) 86:2752–2756.
   PubMed Web of Science ®Google Scholar
• DIMOPOULOU I, TSAGARAKIS S, KOUYIALIS AT et al: Hypothalamic-pituitary-adrenal axis dysfunction in critically ill patients with traumatic brain injury: incidence, pathophysiology, and relationship to vasopressor dependence and peripheral interleukin-6 levels. Grit. Care Med. (2004) 32:404–408.
   PubMed Web of Science ®Google Scholar
• ANNANE D, SE-13TUE V, CHARPENTIER C et al.: Effect of a treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA (2002) 288:862–971.
   Google Scholar
• •A recent trial that highlighted the importance of relative adrenal Insufficiency.
   Google Scholar
• GRUNDY PL, PATEL N, HARBUZ MS, LIGHTMAN SL, SHARPLES PM: Glucocorticoids modulate the NGF mRNA response in the rat hippocampus after traumatic brain injury. Brain Res. (2001) 892:386–390.
   PubMed Web of Science ®Google Scholar
• LECAMWASAM HS, BABOOLAL HA, DUNN PF: Acute adrenal insufficiency after large-dose glucocorticoids for spinal cord injury. Anesth. Analg. (2004) 99:1813–1814.
   PubMed Web of Science ®Google Scholar
• LATRONICO N, PELI E, BOTTERT M: Critical illness myopathy and neuropathy. Curr. Opin. Crit. Care (2005) 11:126–132.
   PubMed Web of Science ®Google Scholar
• ••A complete review on ICUAP.
   Google Scholar
• BOLTON CF: Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Grit. Care Med. (1996) 24:1408–1416.
   PubMed Web of Science ®Google Scholar
• DRUSCHKY A, HERKERT M, RADESPIEL-TROGER M et al.: Critical illness polyneuropathy: clinical findings and cell culture assay of neurotoxicity assessed by a prospective study. Intensive Care Med. (2001) 27:686–693.
   PubMed Web of Science ®Google Scholar
• RICH MM, PINTER MJ: Crucial role ofsodium channel fast inactivation in muscle fibre inexcitability in a rat model of critical illness myopathy. Physiol (2003) 547:555–566.
   Web of Science ®Google Scholar
• MASSA R, CARPENTERS, HOLLAND P, KARPATI G: Loss and renewal of thick myofilaments in glucocorticoid-treated rat soleus after denervation and reinnervation. Muscle Nerve (1992) 15:1290–1298.
   PubMed Web of Science ®Google Scholar
• RICH MM, PINTER MJ, KRANER SD, BARCHI RL: Loss of electrical excitability in an animal model of acute quadriplegic myopathy. Ann. Neurol (1998) 43:171–179.
   PubMed Web of Science ®Google Scholar
• RICH MM, PINTER MJ: Sodium channel inactivation in an animal model of acute quadriplegic myopathy. Ann. Neurol (2001) 50: 26–33.
   PubMed Web of Science ®Google Scholar
• QIAN T, GUO X, LEVI AD, VANNI S, SHEBERT RT, SIPSKI ML: High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients. Spinal Cord (2005) 43:199–203.
   PubMed Web of Science ®Google Scholar
• GUBBA EM, NETHERTON CM, HERBERT J: Endangerment of the brain by glucocorticoids:experimental and clinical evidence. Neurocytol (2000) 29:439–449.
   PubMedGoogle Scholar
• SAPOLSKYGlucocorticoid toxicity in the hippocampus: reversal by supplementation with brain fuels. Neurosci. (1986) 6:2240–2244.
   PubMed Web of Science ®Google Scholar
• VIRGIN CE JR, HA TP, PACKAN DR et al.: Glucocorticoids inhibit glucose transport and glutamate uptake in hippocampal astrocytes: implications for glucocorticoid neurotoxicity. Neurochein. (1991) 57:1422–1428.
   PubMed Web of Science ®Google Scholar
• UHLER TA, FRIM DM, PAKZABAN P, ISACSON O: The effects of megadose methylprednisolone and U-78517F on toxicity mediated by glutamate receptors in the rat neostriatum. Neurosurgery (1994) 34:122–127.
   PubMed Web of Science ®Google Scholar
• TOMBAUGH GC, YANG SH, SWANSON RA, SAPOLSKY Glucocorticoids exacerbate hypoxic and hypoglycemic hippocampal injury in vitro: biochemical correlates and a role for astrocytes. I Neurochein. (1992) 59:137–146.
   PubMed Web of Science ®Google Scholar